CMB305 Immunotherapy Regimen Demonstrates 83% OS Rate in Sarcoma, 1-Year Data Shows – Targeted Oncology
Targeted Oncology |
CMB305 Immunotherapy Regimen Demonstrates 83% OS Rate in Sarcoma, 1-Year Data Shows
Targeted Oncology CMB305, an immunotherapy regimen that generates and expands anti-NY-ESO-1 T cells, demonstrated a favorable survival rate in patients with recurrent soft tissue sarcoma, compared with other agents approved for the disease, according to results of a … |
